TransCode Therapeutics, Inc.
RNAZ
$1.77
-$0.13-6.61%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 58.48% | 30.97% | -3.08% | 4.33% | -20.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 73.10% | 50.23% | 22.55% | 16.23% | -17.75% |
| Operating Income | -73.10% | -50.23% | -22.55% | -16.23% | 17.75% |
| Income Before Tax | -72.27% | -56.40% | -105.52% | -81.78% | -37.39% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -74.13% | -58.19% | -106.87% | -81.78% | -37.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -74.13% | -58.19% | -106.87% | -81.78% | -37.39% |
| EBIT | -73.10% | -50.23% | -22.55% | -16.23% | 17.75% |
| EBITDA | -73.06% | -50.37% | -22.78% | -16.83% | 17.45% |
| EPS Basic | 89.90% | 90.21% | 77.16% | -148.08% | -- |
| Normalized Basic EPS | 94.59% | 94.87% | 79.41% | -147.10% | -- |
| EPS Diluted | 89.90% | 90.21% | 77.16% | -148.08% | -- |
| Normalized Diluted EPS | 94.59% | 94.87% | 79.41% | -147.10% | -- |
| Average Basic Shares Outstanding | 247.17% | 1,571.05% | 7,340.00% | 11,603.14% | -- |
| Average Diluted Shares Outstanding | 247.17% | 1,571.05% | 7,340.00% | 11,603.14% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |